Format

Send to

Choose Destination
Biomed Pharmacother. 2018 Feb;98:297-307. doi: 10.1016/j.biopha.2017.12.053. Epub 2017 Dec 27.

Recent advances in the neurobiology and neuropharmacology of Alzheimer's disease.

Author information

1
Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga 142001, Punjab, India; Defence Institute of High Altitude Research, C/o 56 APO-901205, Leh-Ladakh, India. Electronic address: kushal1kumar@gmail.com.
2
Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga 142001, Punjab, India.
3
Department of Neurobiology and Behavior, Stony Brook University, Stony Brook, NY, USA.

Abstract

Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by progressive deterioration of cognitive functions. The pathological hallmarks are extracellular deposits of amyloid plaques and intracellular neurofibrillary tangles of tau protein. The cognitive deficits seen are thought to be due to synaptic dysfunction and neurochemical deficiencies. Various neurochemical abnormalities have been observed during progressive ageing, and are linked to cognitive abnormalities as seen with the sporadic form of AD. Acetylcholinesterase inhibitors are one of the major therapeutic strategies used for the treatment of AD. During the last decade, various new therapeutic strategies have shown beneficial effects in preclinical studies and under clinical development for the treatment of AD. The present review is aimed at discussing the neurobiology of AD and association of neurochemical abnormalities associated with cognitive deterioration and new therapeutic strategies for the treatment of AD.

KEYWORDS:

Acetylcholine; Alzheimer's disease; Amyloid plaques; Neurofibrillary tangles; New therapeutic strategies

PMID:
29274586
DOI:
10.1016/j.biopha.2017.12.053
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center